Actio locks in $55M Series A raise to advance rare disease pipeline based on human genetic platform
Actio Biosciences has secured a Series A raise worth $55 million to advance its clinical pipeline in rare diseases, particularly in patients with ion channel TRPV4 mutations.
The San Diego, CA-headquartered company has three assets in its pipeline, led by its unnamed preclinical small molecule program under investigation for Charcot-Marie-Tooth disease type 2C (CMT2C) and other rare bone diseases. CMT2C is caused by mutations in TRPV4.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.